Pell Bio-Med Technology Past Earnings Performance
Past criteria checks 0/6
Pell Bio-Med Technology's earnings have been declining at an average annual rate of -29.1%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 7.1% per year.
Key information
-29.1%
Earnings growth rate
-14.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 7.1% |
| Return on equity | -28.3% |
| Net Margin | -2,097.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Pell Bio-Med Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 18 | -386 | 137 | 261 |
| 30 Jun 24 | 18 | -404 | 148 | 256 |
| 31 Mar 24 | 18 | -425 | 158 | 254 |
| 31 Dec 23 | 18 | -399 | 145 | 240 |
| 30 Sep 23 | 20 | -361 | 134 | 212 |
| 30 Jun 23 | 20 | -310 | 115 | 187 |
| 31 Mar 23 | 19 | -238 | 88 | 146 |
| 31 Dec 22 | 17 | -230 | 82 | 143 |
| 31 Dec 21 | 14 | -189 | 55 | 137 |
Quality Earnings: 6949 is currently unprofitable.
Growing Profit Margin: 6949 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6949's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6949's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6949 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 6949 has a negative Return on Equity (-28.35%), as it is currently unprofitable.